Gadolinium-based Contrast Agents Improve Detection of Recurrent Soft-Tissue Sarcoma at MRI.

Area of Science:

• Radiology
• Oncology
• Medical Imaging

Background:

• Soft-tissue sarcomas are rare cancers requiring accurate follow-up imaging.
• Recurrence detection is crucial for timely treatment adjustment.
• Conventional MRI sequences may have limitations in differentiating scar tissue from tumor recurrence.

Purpose of the Study:

• To evaluate the diagnostic efficacy of gadolinium-based contrast agents (GBCAs) for detecting recurrent soft-tissue sarcoma.
• To compare the performance of contrast-enhanced MRI with non-contrast-enhanced sequences.

Main Methods:

• Retrospective analysis of 69 patients with recurrent soft-tissue sarcoma and 63 controls.
• Six musculoskeletal radiologists reviewed MRI studies in three image groupings: non-contrast, contrast-enhanced T1-weighted, and combined contrast-enhanced T1- and T2-weighted sequences.
• Receiver operating characteristic (ROC) analysis was used to assess diagnostic performance.

Main Results:

• Contrast-enhanced MRI (Groups 2 and 3) demonstrated significantly higher sensitivity and Area Under the Curve (AUC) compared to non-contrast MRI (Group 1).
• Group 3 (contrast-enhanced T1- and T2-weighted) showed a modest sensitivity improvement over Group 2 (contrast-enhanced T1-weighted only).
• Specificity did not significantly differ between the groups.

Conclusions:

• Gadolinium-based contrast agents enhance the diagnostic performance for recurrent soft-tissue sarcoma detection.
• The addition of fat-saturated T2-weighted images provides a marginal benefit in sensitivity.
• Contrast-enhanced MRI is a valuable tool for monitoring soft-tissue sarcoma recurrence.